BTOG 2023 | The evolving oncology landscape: a radiotherapy perspective

Kevin Franks, MBChB, MRCP, FRCR, University of Leeds, Leeds, UK, outlines how radiotherapy fits into the changing oncology landscape. He touches on the significance of both the Phase III CheckMate 816 study (NCT02998528) and PACIFIC study (NCT02125461) in highlighting the value of chemoimmunotherapy in both resectable and unrespectable non-small cell lung cancer (NSCLC) populations. While these results call into question whether the surgical approach to NSCLC ought to be adjusted, the present consensus is to retain pre-existing approaches until a more detailed understanding of influential biomarkers is achieved. He outlines the ongoing debates of employing chemoradiotherapy prior to surgery, despite the surgical challenges it can create, and the significance and safety of using radiotherapy in both progressive and N2 disease states. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.